Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II
clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits …

We have documented that epidermal growth factor receptor protein tyrosine kinase (EGFR-
PTK) signaling negatively affects intracellular trafficking and transduction efficiency of …

Adeno-associated virus (AAV) based vectors have emerged as important tools for gene
therapy in humans. The recent successes seen in Phase I/II clinical trials have also …

Recombinant adeno-associated virus (rAAV) vectors are unique among the vector classes
currently available for human gene therapy in that they are based upon a class of viruses …

Recombinant adeno-associated virus (AAV) vectors are of interest in the context of gene
therapy because of their ability to mediate efficient transfer and stable expression of …

Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the
treatment of a variety of human diseases. Recent advances in developing clinically …

Recombinant gene delivery vectors derived from naturally occurring or genetically
engineered adeno-associated viruses (AAV) have taken center stage in human gene …

Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of
gene therapy in the past decade. The exponential progress of AAV-based vectors has been …

In the last two decades, recombinant adeno-associated virus has emerged as the most
popular gene therapy vector. Recently AAV gene therapy has been approved by the FDA for …

Gene therapy with adeno-associated viral (AAV) vectors has reached the clinical stage for
many inherited and acquired diseases. However, due to a cargo capacity limited to< 5 kb …